157 related articles for article (PubMed ID: 23044454)
1. Prevalence of hypothyroidism among MDR-TB patients in Botswana.
Modongo C; Zetola NM
Int J Tuberc Lung Dis; 2012 Nov; 16(11):1561-2. PubMed ID: 23044454
[No Abstract] [Full Text] [Related]
2. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.
Tembo BP; Malangu NG
BMC Infect Dis; 2019 Sep; 19(1):779. PubMed ID: 31492099
[TBL] [Abstract][Full Text] [Related]
3. Is hypothyroidism rare in multidrug resistance tuberculosis patients on treatment? A systematic review and meta-analysis.
Tola HH; Holakouie-Naieni K; Lejisa T; Mansournia MA; Yaseri M; Tesfaye E; Mola M
PLoS One; 2019; 14(6):e0218487. PubMed ID: 31211809
[TBL] [Abstract][Full Text] [Related]
4. High rate of hypothyroidism among patients treated for multidrug-resistant tuberculosis in Lesotho.
Satti H; Mafukidze A; Jooste PL; McLaughlin MM; Farmer PE; Seung KJ
Int J Tuberc Lung Dis; 2012 Apr; 16(4):468-72. PubMed ID: 22326109
[TBL] [Abstract][Full Text] [Related]
5. Impact of the human immunodeficiency virus on early multidrug-resistant tuberculosis treatment outcomes in Botswana.
Hafkin J; Modongo C; Newcomb C; Lowenthal E; MacGregor RR; Steenhoff AP; Friedman H; Bisson GP
Int J Tuberc Lung Dis; 2013 Mar; 17(3):348-53. PubMed ID: 23321297
[TBL] [Abstract][Full Text] [Related]
6. Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis.
Muñoz-Torrico M; Caminero-Luna J; Migliori GB; D'Ambrosio L; Carrillo-Alduenda JL; Villareal-Velarde H; Torres-Cruz A; Flores-Vergara H; Martínez-Mendoza D; García-Sancho C; Centis R; Salazar-Lezama MÁ; Pérez-Padilla R
Arch Bronconeumol; 2017 May; 53(5):245-250. PubMed ID: 28089216
[TBL] [Abstract][Full Text] [Related]
7. Hypothyroidism in a patient receiving treatment for multidrug-resistant tuberculosis.
Soumakis SA; Berg D; Harris HW
Clin Infect Dis; 1998 Oct; 27(4):910-1. PubMed ID: 9798062
[No Abstract] [Full Text] [Related]
8. Hypothyroidism associated with therapy for multi-drug-resistant tuberculosis in Australia.
Cheung YM; Van K; Lan L; Barmanray R; Qian SY; Shi WY; Wong JLA; Hamblin PS; Colman PG; Topliss DJ; Denholm JT; Grossmann M
Intern Med J; 2019 Mar; 49(3):364-372. PubMed ID: 30151969
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced hypothyroidism in patients receiving treatment for multidrug-resistant tuberculosis in the UK.
Gupta J; Breen RA; Milburn HJ
Int J Tuberc Lung Dis; 2012 Sep; 16(9):1278. PubMed ID: 22871328
[No Abstract] [Full Text] [Related]
10. Hypothyroidism due to ethionamide.
McDonnell ME; Braverman LE; Bernardo J
N Engl J Med; 2005 Jun; 352(26):2757-9. PubMed ID: 15987931
[No Abstract] [Full Text] [Related]
11. Ethionamide-induced hypothyroidism.
Dutta BS; Hassan G; Waseem Q; Saheer S; Singh A
Int J Tuberc Lung Dis; 2012 Jan; 16(1):141. PubMed ID: 22236862
[No Abstract] [Full Text] [Related]
12. Evaluation of risk factors associated with drug-resistant tuberculosis in Yemen: data from centres with high drug resistance.
Jaber AAS; Ibrahim B
BMC Infect Dis; 2019 May; 19(1):464. PubMed ID: 31126246
[TBL] [Abstract][Full Text] [Related]
13. Adverse events in an integrated home-based treatment program for MDR-TB and HIV in KwaZulu-Natal, South Africa.
Brust JC; Shah NS; van der Merwe TL; Bamber S; Ning Y; Heo M; Moll AP; Loveday M; Lalloo UG; Friedland GH; Gandhi NR
J Acquir Immune Defic Syndr; 2013 Apr; 62(4):436-40. PubMed ID: 23254152
[TBL] [Abstract][Full Text] [Related]
14. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM
Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505
[TBL] [Abstract][Full Text] [Related]
15. Converging risk factors but no association between HIV infection and multidrug-resistant tuberculosis in Kazakhstan.
van den Hof S; Tursynbayeva A; Abildaev T; Adenov M; Pak S; Bekembayeva G; Ismailov S
Int J Tuberc Lung Dis; 2013 Apr; 17(4):526-31. PubMed ID: 23485387
[TBL] [Abstract][Full Text] [Related]
16. Hypothyroidism during second-line treatment of multidrug-resistant tuberculosis: a prospective study.
Bares R; Khalid N; Daniel H; Dittmann H; Reimold M; Gallwitz B; Schmotzer C
Int J Tuberc Lung Dis; 2016 Jul; 20(7):876-81. PubMed ID: 27287638
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and factors associated with multidrug-resistant tuberculosis in South India.
Shivekar SS; Kaliaperumal V; Brammacharry U; Sakkaravarthy A; Raj CKV; Alagappan C; Muthaiah M
Sci Rep; 2020 Oct; 10(1):17552. PubMed ID: 33067551
[TBL] [Abstract][Full Text] [Related]
18. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
[TBL] [Abstract][Full Text] [Related]
19. Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India.
Isaakidis P; Varghese B; Mansoor H; Cox HS; Ladomirska J; Saranchuk P; Da Silva E; Khan S; Paryani R; Udwadia Z; Migliori GB; Sotgiu G; Reid T
PLoS One; 2012; 7(7):e40781. PubMed ID: 22792406
[TBL] [Abstract][Full Text] [Related]
20. Factors related to previous tuberculosis treatment of patients with multidrug-resistant tuberculosis in Bangladesh.
Rifat M; Hall J; Oldmeadow C; Husain A; Hinderaker SG; Milton AH
BMJ Open; 2015 Sep; 5(9):e008273. PubMed ID: 26351185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
